ArticleRadiation oncology (London, England)2017
Validation of the graded prognostic assessment for lung cancer with brain metastases using molecular markers (lung-molGPA).
Article in Radiation oncology (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Efficacy and safety of combining bevacizumab and fractionated stereotactic radiotherapy for extensive brain metastases in patients with non-small cell lung cancer: a prospective phase II study (GASTO-1053).Cancer communications (London, England) · 2025Trial
- External validation of the graded prognostic assessment for patients with non-small cell lung cancer and brain metastases using molecular markers (Lung-molGPA).Radiation oncology journal · 2026Article
- Development of brain metastases in patients managed with non-curative thoracic radiotherapy for stage II/III non-small cell lung cancer.Discover oncology · 2024Article
- Article
- Validation of the ALK-Brain Prognostic Index for patients with ALK-rearranged lung cancer and brain metastases.ESMO open · 2023Article
- Brain metastases in Japanese NSCLC patients: prognostic assessment and the use of osimertinib and immune checkpoint inhibitors-retrospective study.Radiation oncology (London, England) · 2023Article
- Primary systemic therapy for patients with brain metastases from lung cancer ineligible for targeted agents.Journal of cancer research and clinical oncology · 2022Article
- External Validation of the Graded Prognostic Assessment in Patients with Brain Metastases from Small Cell Lung Cancer.Current oncology (Toronto, Ont.) · 2022Article
- Predictors of Lung Adenocarcinoma With Leptomeningeal Metastases: A 2022 Targeted-Therapy-Assisted molGPA Model.Frontiers in oncology · 2022Article
- Stereotactic radiotherapy for brain metastases in patients with lung cancer; outcome and toxicity in clinical practice.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2022Article
- Low Heart Rate Variability Predicts Poor Overall Survival of Lung Cancer Patients With Brain Metastases.Frontiers in neuroscience · 2022Article
- Population-based estimates of survival among elderly patients with brain metastases.Neuro-oncology · 2021Article
- Individualized Nomogram for Predicting Survival in Patients with Brain Metastases After Stereotactic Radiosurgery Utilizing Driver Gene Mutations and Volumetric Surrogates.Frontiers in oncology · 2021Article
- Article
- Article
- Validation of the graded prognostic assessment for gastrointestinal cancers with brain metastases (GI-GPA).Radiation oncology (London, England) · 2020Article
- Article
- Observational
- Role of perilesional edema and tumor volume in the prognosis of non-small cell lung cancer (NSCLC) undergoing radiosurgery (SRS) for brain metastases.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2019Article
- External validation of a prognostic score predicting overall survival for patients with brain metastases based on extracranial factors.Clinical and translational radiation oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMany patients with brain metastases from non-small cell lung cancer have limited survival, while others survive for several years, depending on patterns of spread, EGFR and ALK alterations, among others. The purpose of this study was to validate a new prognostic model (Lung-molGPA) originally derived from a North American database. PATIENTS AND
methodsThis retrospective study included 269 German and Norwegian patients treated with individualized approaches, always including brain radiotherapy. Information about age, extracranial spread, number of brain metastases, performance status, histology, EGFR and ALK alterations was collected. The Lung-molGPA score was calculated as described by Sperduto et al.
resultsMedian survival was 5.4 months. The score predicted survival in patients with adenocarcinoma histology and those with other types. For example, median survival was 3.0, 6.2, 14.7 and 25.0 months in the 4 different prognostic strata for adenocarcinoma. The corresponding figures were 2.4, 5.5 and 12.5 months in the 3 different prognostic strata for non-adenocarcinoma.
conclusionsThese results confirm the validity of the Lung-molGPA in an independent dataset from a different geographical region. However, median survival was shorter in 6 of 7 prognostic strata. Potential explanations include lead time bias and differences in treatment selection, both brain metastases-directed and systemically.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.